Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 entities : Acurx pharmaceuticals llc save search
Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases
Published: 2022-02-07 (Crawled : 13:30) - prnewswire.com
ACXP | $2.04 7K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 1.52%
C: 0.51%
phase 2 trial trial results disease infectious disease positive phase 2b
Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI)
Published: 2021-12-06 (Crawled : 14:00) - biospace.com/
ACXP | $2.04 7K
|
Professional, Scientific, and T...
|
| O: 2.41%
H: 4.47%
C: 2.82%
treatment phase 2 phase 2b trial infection iot enroll infections
Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference
Published: 2021-11-08 (Crawled : 13:15) - prnewswire.com
ACXP | $2.04 7K
|
Professional, Scientific, and T...
|
| O: 5.06%
H: 1.6%
C: 0.53%
phase 2 trial conference phase 2b
Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference
Published: 2021-11-01 (Crawled : 12:00) - prnewswire.com
ACXP | $2.04 7K
|
Professional, Scientific, and T...
|
| O: 0.2%
H: 11.38%
C: 9.18%
phase 2 trial conference phase 2b
Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek
Published: 2021-10-04 (Crawled : 14:00) - biospace.com/
ACXP | $2.04 7K
|
Professional, Scientific, and T...
|
| O: -9.31%
H: 9.42%
C: -1.38%
phase 2 positive trial phase 2b
Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI in a Scientific Poster Presentation at IDWeek 2021 Conference
Published: 2021-09-27 (Crawled : 13:00) - biospace.com/
ACXP | $2.04 7K
|
Professional, Scientific, and T...
|
| O: 0.57%
H: 7.26%
C: 0.91%
presentation phase 2 trial conference phase 2b
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $1.93 64.96% 55M
|
AMST | $3.14 57.0% 59M
|
Technology Services
LICN | $0.7885 40.8% 11M
|
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.